Cohance Lifesciences Share Price Today | Stock Price & Cohance Lifesciences Share Screener
As of November 18, 2026, the live Cohance Lifesciences share price (NSE: COHANCE) is ₹456.40 on NSE and ₹456.40 on BSE, up 1.06% from the previous close, with shares trading between ₹445.25 and ₹457.95 in today's trading session, and a 52-week range of ₹279.90–₹589.30. Track COHANCE market cap trends to gauge the company's total market size. Use the Cohance Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Cohance Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹617 and net income of ₹8, with EBITDA of ₹80, an operating margin of 13.0% and a profit margin of 1.3%.
Cohance Lifesciences Share Price Chart
Track the current stock price of Cohance Lifesciences with an interactive chart. Analyse COHANCE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Cohance Lifesciences stock quote in one place.
The quote of ₹456.40 sits between the 52-week low of ₹279.90 and the 52-week high of ₹589.30, and the latest session moved 1.06% from the previous close.
Cohance Lifesciences Company Profile - Fundamental Screener
Screen Cohance Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for COHANCE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Umang Vohra listed as chairperson or CEO, and it trades under ISIN INE03QK01018.
Business Overview
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Company Details
Classification
Identifiers and Leadership
Cohance Lifesciences Balance Sheet Screener
Screen COHANCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹5,730, up from ₹5,481 in 2025.
Latest statistics put total assets at ₹5,730 and shareholder funds at ₹4,034, with a leverage ratio of 0.12.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 5,730 | 5,481 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 3,369 | 3,107 | 670 | 663 | 534 | 441 | 357 | 271 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,050 | 983 | 97 | 72 | 92 | 74 | 128 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 4,034 | 3,793 | 2,051 | 1,735 | 1,527 | 1,181 | 845 | 590 |
| Share Capital | 38 | 26 | 26 | 26 | 26 | 26 | 13 | 13 |
| Reserves & Surplus | 3,873 | 3,604 | 2,025 | 1,710 | 1,502 | 1,155 | 832 | 578 |
Cohance Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Cohance Lifesciences income statement and profit fundamentals. Analyze COHANCE quarterly results. Cohance Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹617 and net profit was ₹8, equal to earnings per unit of ₹0.51, at an operating margin of 13%.
In that period expenses were ₹537, interest cost ₹9 and tax ₹12. The next period listed, 2026-Jun, shows revenue of ₹435 and net profit of ₹-45.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 617 | 435 | 489 | 853 | 564 | 571 | 551 | 270 | 508 | 620 | 698 | 381 | 358 | 251 | 234 |
| Expenses | 537 | 421 | 441 | 627 | 445 | 435 | 454 | 180 | 363 | 398 | 439 | 198 | 181 | 133 | 154 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 80 | 13 | 48 | 226 | 118 | 137 | 97 | 90 | 145 | 222 | 259 | 183 | 178 | 118 | 80 |
| Operating Profit % | 13.00% | 0.00% | 7.00% | 25.00% | 19.00% | 22.00% | 17.00% | 29.00% | 26.00% | 34.00% | 35.00% | 47.00% | 48.00% | 42.00% | 30.00% |
| Depreciation | 51 | 50 | 50 | 54 | 45 | 44 | 47 | 17 | 31 | 38 | 44 | 12 | 13 | 12 | 13 |
| Interest | 9 | 7 | 8 | 10 | 10 | 9 | 9 | 2 | 10 | 10 | 11 | 5 | 1 | 1 | 2 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 20 | -43 | -11 | 161 | 63 | 84 | 41 | 71 | 103 | 174 | 205 | 166 | 164 | 105 | 66 |
| Tax | 12 | 2 | -13 | 44 | 16 | 17 | 12 | 18 | 28 | 36 | 51 | 42 | 43 | 26 | 19 |
| Net Profit | 8 | -45 | 2 | 117 | 46 | 66 | 29 | 53 | 75 | 138 | 154 | 124 | 121 | 80 | 47 |
| EPS | 0.51 | -0.63 | 0.40 | 3.16 | 1.28 | 1.94 | 0.96 | 2.10 | 1.98 | 3.63 | 4.02 | 4.87 | 4.74 | 3.13 | 1.84 |
Cohance Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen COHANCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹368, and net cash flow was an outflow of ₹48.
Over the same period, investing activities used ₹251 and financing activities used ₹165.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||
| Operating Activities | 368 | 673 | 359 | 457 | 330 | 383 | 407 | 50 |
| Investing Activities | -251 | -388 | -362 | -195 | -136 | -311 | -414 | -66 |
Financing and Net Cash | ||||||||
| Financing Activities | -165 | -327 | -14 | -242 | -156 | -76 | 7 | 26 |
| Net Cash Flow | -48 | -42 | -18 | 20 | 37 | -5 | 1 | 11 |
Cohance Lifesciences Shareholding Pattern Screener
See Cohance Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check Cohance Lifesciences promoter holding and ownership changes for COHANCE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 57.49%, foreign institutions 5.59%, domestic institutions 21.79% and the public 7.04%, spread across 85,230 shareholders.
The shareholder count was 85,230 in 2026-Mar, compared with 99,149 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-May | 2025-Jun | 2025-Sept | 2025-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 57.49% | 57.49% | 57.48% | 50.10% | 66.41% | 66.41% | 57.49% | 57.49% |
Institutional Investors | ||||||||
| FII Holding | 5.59% | 6.50% | 7.71% | 11.05% | 7.38% | 7.23% | 6.51% | 6.02% |
| DII Holding | 21.79% | 20.09% | 18.86% | 16.60% | 11.02% | 11.40% | 20.82% | 21.57% |
Government, Public and Others | ||||||||
| Govt Holding | 0.01% | 0.01% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 7.04% | 7.71% | 7.50% | 9.68% | 6.63% | 6.40% | 6.42% | 6.76% |
| Other Holding | 8.08% | 8.21% | 8.46% | 12.55% | 8.55% | 8.55% | 8.75% | 8.16% |
| Shareholder Count | 85,230 | 99,149 | 93,846 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Cohance Lifesciences. Cohance Lifesciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹6.00 | 0.89% |
| 2022-March | ₹5.00 | 1.06% |
| 2021-March | ₹2.00 | 0.32% |
| 2020-March | ₹5.00 | 1.01% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Cohance Lifesciences Stock Index Membership - Nifty & Sensex
See which indices include Cohance Lifesciences stock. Check COHANCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 20 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Cohance Lifesciences Market Events Screener - Corporate Actions
Get Cohance Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Cohance Lifesciences stock events that may affect COHANCE share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.
It is followed by Annual General Meeting dated September 17, 2026 and Quarterly Result Announcement dated August 5, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-06 | 2026-11-06 | Quarterly Result Announcement | NA | -0.03% |
| 2026-09-17 | 2026-09-17 | Annual General Meeting | NA | 1.89% |
| 2026-08-05 | 2026-08-05 | Quarterly Result Announcement | NA | -2.94% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 5.46% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -33.96% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -20.48% |
| 2025-09-19 | 2025-09-19 | Annual General Meeting | NA | -6.87% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -5.19% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -5.13% |
| 2025-05-07 | 2025-05-07 | Change Of Name | NA | 0.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.54% |
| 2024-11-28 | 2024-11-28 | Extraordinary General Meeting | NA | -0.62% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 4.44% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 16.74% |
| 2023-12-15 | 2023-12-15 | Annual General Meeting | NA | 17.68% |
Cohance Lifesciences Competitors Screener - Peer Stocks Comparison
Screen COHANCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Cohance Lifesciences Company Announcements - News & Reports Screener
Screen COHANCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 14, 2026.
The next most recent announcements are dated November 14, 2026 and November 13, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-14 | Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-11-14 | Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-13 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-11-13 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-11-09 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-09 | Update On USFDA Inspection For CompanyS Pashamylaram Manufacturing Facility | - |
| 2026-11-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-06 | Outcome Of The Board Meeting | - |
| 2026-11-06 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-11-06 | Grant Of Stock Options To Certain Eligible Employees Of The Company And Allotment Of Equity Shares Pursuant To Exercise Of Stock Options | - |
| 2026-11-06 | General Announcement | - |
| 2026-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-26 | Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2026 | - |
| 2026-10-12 | General Updates | - |
| 2026-10-09 | Grant Of Stock Options To Certain Eligible Employees Of The Company | - |
| 2026-10-09 | Announcement under Regulation 30 (LODR)-Change in Management | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹456.40, within a 52-week range of ₹279.90 to ₹589.30. The P/E ratio is -3049.70 and the P/B ratio is 4.47, with earnings per unit of ₹4.69. Market capitalisation stands at ₹17,278.10 Cr and the dividend yield is 1.31%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.